Simcere Signs an Exclusive Regional Licensing Agreement with GI Innovation for its GI-101 Candidate

Shots:

• GI to receive up front, milestones, and royalties on sales in China, including mainland China, Hong Kong, Macau, and Taiwan while Simcere will be responsible for all clinical development, regulatory approval and commercialization of the assets in territories
• The focus of the collaboration is to develop monotherapy as well as combination therapy with immune checkpoint inhibitors for multiple cancer indications while jointly enhancing clinical development of cancer therapies
• GI-101 is a novel immune-cytokine bi-specific fusion candidate developed using GI Innovation’s GI-SMART platform targeted to treat solid tumors  

Click here to­ read full press release/ article | Ref: Simcere | Image: Twitter